Have a feature idea you'd love to see implemented?
Let us know!
EYEN Eyenovia Inc
Price (delayed)
$0.442
Market cap
$28.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.78
Enterprise value
$41.68M
Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for
Highlights
Eyenovia's debt has decreased by 6% from the previous quarter and by 2.9% YoY
The company's equity has shrunk by 123% YoY
The company's quick ratio has shrunk by 97% YoY and by 69% QoQ
Key stats
What are the main financial stats of EYEN
Market
Valuations
Earnings
Shares outstanding
64.06M
Market cap
$28.31M
Enterprise value
$41.68M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
747.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,327.03
Revenue
$31,405
EBIT
-$34.57M
EBITDA
-$33.43M
Free cash flow
-$32.24M
Per share
Balance sheet
Liquidity
EPS
-$0.78
Free cash flow per share
-$0.61
Book value per share
-$0.04
Revenue per share
$0
TBVPS
$0.24
Total assets
$18.99M
Total liabilities
$21.36M
Debt
$15.66M
Equity
-$2.37M
Working capital
-$8.56M
Debt to equity
-6.61
Current ratio
0.46
Quick ratio
0.15
Net debt/EBITDA
-0.4
Margins
Efficiency
Dividend
EBITDA margin
-106,448.3%
Gross margin
-1,433.5%
Net margin
-118,712.5%
Operating margin
-114,390.5%
Return on assets
-137%
Return on equity
-615.5%
Return on invested capital
-221.3%
Return on capital employed
-1,098.7%
Return on sales
-110,075.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EYEN stock price
How has the Eyenovia stock price performed over time
Intraday
-1.78%
1 week
-6.16%
1 month
-24.47%
1 year
-71.11%
YTD
-78.75%
QTD
-14.44%
Financial performance
How have Eyenovia's revenue and profit performed over time
Revenue
$31,405
Gross profit
-$450,176
Operating income
-$35.92M
Net income
-$37.28M
Gross margin
-1,433.5%
Net margin
-118,712.5%
Eyenovia's net margin has soared by 68% from the previous quarter
The operating margin has soared by 67% QoQ
EYEN's operating income is down by 50% YoY and by 19% from the previous quarter
Eyenovia's net income has decreased by 47% YoY and by 15% QoQ
Growth
What is Eyenovia's growth rate over time
Valuation
What is Eyenovia stock price valuation
P/E
N/A
P/B
N/A
P/S
747.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,327.03
The EPS has contracted by 15% YoY and by 7% from the previous quarter
The company's equity has shrunk by 123% YoY
The P/S is 96% below the last 4 quarters average of 21098.8
Efficiency
How efficient is Eyenovia business performance
The ROE has shrunk by 76% QoQ
The ROS has soared by 68% from the previous quarter
Eyenovia's ROA has plunged by 63% YoY and by 26% from the previous quarter
Eyenovia's ROIC has decreased by 41% from the previous quarter and by 35% YoY
Dividends
What is EYEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EYEN.
Financial health
How did Eyenovia financials performed over time
The total assets is 11% smaller than the total liabilities
The company's quick ratio has shrunk by 97% YoY and by 69% QoQ
Eyenovia's current ratio has plunged by 92% YoY and by 48% from the previous quarter
Eyenovia's debt to equity has shrunk by 172% QoQ
The company's equity has shrunk by 123% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.